Covalon Successfully Signs Distribution Agreements and Commences Sales in Nine Countries within Vast Latin American Market

MISSISSAUGA, Ontario–(BUSINESS WIRE)–Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV), an
advanced medical technologies company, today announced that it has
signed distribution agreements and commenced sales of its line of
innovative Infection Control and Advanced Wound Care products into nine
countries in Latin America.
Covalon’s products are now immediately available in Argentina, Chile,
Guatemala, Honduras, Nicaragua, El Salvador, Costa Rica, Panama and
Puerto Rico.
Covalon expects to have its products cleared in Mexico, Colombia, Peru,
Venezuela, Ecuador, Dominican Republic, Paraguay and Uruguay by the end
of 2016. Regulatory clearance in Brazil is expected in 2017.
With over 600 million people in Latin America and significantly higher
rates of hospital-acquired infections as compared to the United States,
Covalon’s products will provide advanced options for Latin American
clinicians to help reduce infections and promote the healing of chronic
wounds when used as part of appropriate clinical protocols.
“Following our extremely successful attendance at the Hospitalar trade
show in Sao Paulo, Brazil on May 17-20, 2016, we are more convinced than
ever that our proven business model used in other regions, such as the
Middle East, will allow Covalon to rapidly grow our presence in Latin
America,” said Brian Pedlar, Covalon’s Chief Executive Officer. “It has
become clear that our products are uniquely positioned to address many
of the clinical treatment gaps currently found in the Latin American
infection control and advanced wound care markets. We are pleased with
our rapid entrance into nine countries in Latin America to date. We are
encouraged by the positive results of the multiple evaluations of our
products underway by key opinion leaders in the region.”
Covalon offers infection management and advanced wound management
dressings for both acute and chronic wounds, including its CovaWound™
ColActive® and SurgiClear™ brands that have strong clinical evidence to
support their superior efficacy in helping to prevent infections in
surgical procedures or in chronic diabetic foot wounds. ColActive and
CovaWound when used together have the ability to rapidly promote wound
closure and healing in chronic wounds, which remains an under-addressed
market in Latin America.
About Covalon
Covalon Technologies Ltd. researches, develops
and commercializes new healthcare technologies that help save lives
around the world. Covalon’s patented technologies, products and services
address the advanced healthcare needs of medical device companies,
healthcare providers and individual consumers. Covalon’s technologies
are used to prevent, detect and manage medical conditions in specialty
areas such as wound care, tissue repair, infection control, disease
management, medical device coatings and biocompatibility. To learn more
about Covalon, visit our website at www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect
the Company’s current expectations regarding future events. The
forward-looking statements are often, but not always, identified by the
use of words such as “seek”, “anticipate”, “plan, “estimate”, “expect”,
“intend” and statements that an event or result “may”, “will”, “should”,
“could” or “might” occur or be achieved and other similar expressions.
These forward-looking statements involve risk and uncertainties,
including the difficulty in predicting product approvals, acceptance of
and demands for new products, the impact of the products and pricing
strategies of competitors, delays in developing and launching new
products, the regulatory environment, fluctuations in operating results
and other risks, any of which could cause results, performance, or
achievements to differ materially from the results discussed or implied
in the forward-looking statements. Many risks are inherent in the
industry; others are more specific to the Company. Investors should
consult the Company’s ongoing quarterly filings for additional
information on risks and uncertainties relating to these forward-looking
statements. Investors should not place undue reliance on any
forward-looking statements. The Company assumes no obligation to update
or alter any forward-looking statements whether as a result of new
information, further events or otherwise.